Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study
暂无分享,去创建一个
[1] G. Livingston,et al. Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial , 2012, PloS one.
[2] Martin Knapp,et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.
[3] J. Hippisley-Cox,et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study , 2011, BMJ : British Medical Journal.
[4] P. Rochon,et al. Antidepressants for agitation and psychosis in dementia. , 2011, The Cochrane database of systematic reviews.
[5] L. Schneider,et al. Trends in antipsychotic use in dementia 1999-2007. , 2011, Archives of general psychiatry.
[6] C. Lyketsos,et al. Management of agitation and aggression associated with Alzheimer disease , 2009, Nature Reviews Neurology.
[7] C. Ballard,et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial , 2009, The Lancet Neurology.
[8] F. Pasquier,et al. Evaluation of the Impact of Memantine Treatment Initiation on Psychotropics Use: A Study from the French National Health Care Database , 2008, Neuroepidemiology.
[9] J. Georges,et al. Alzheimer's disease in real life – the dementia carer's survey , 2008, International journal of geriatric psychiatry.
[10] S. Gauthier,et al. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.
[11] C. Ballard,et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.
[12] Peter Short,et al. Connecting for health. , 2008, The British journal of general practice : the journal of the Royal College of General Practitioners.
[13] Constantine G Lyketsos,et al. Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study , 2008, International journal of geriatric psychiatry.
[14] Martin Knapp,et al. Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.
[15] Stephen Humphreys,et al. Connecting for health. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.
[16] Daniel Weintraub,et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. , 2006, The New England journal of medicine.
[17] Philip S. Insel,et al. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[18] J. Avorn,et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.
[19] Lon S Schneider,et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.
[20] David Craig,et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[21] D. Craig,et al. The future of memory clinics , 2004 .
[22] P. Modrego,et al. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. , 2004, Archives of neurology.
[23] C. Holmes,et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease , 2004, Neurology.
[24] Kristine Yaffe,et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.
[25] C. Lyketsos,et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. , 2002, JAMA.
[26] A K Wagner,et al. Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.
[27] Kristine Yaffe,et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. , 2002, JAMA.
[28] G A Chase,et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.
[29] Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease , 2010 .
[30] F. Sherriff,et al. Memantine for dementia. , 2005, The Cochrane database of systematic reviews.